Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar 19;106(5):842-53.
doi: 10.1161/CIRCRESAHA.109.212217.

The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature

Shi Fang Yan  1 , Ravichandran Ramasamy, Ann Marie Schmidt
Affiliations
Review

The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature

Shi Fang Yan et al. Circ Res. .

Erratum in

  • Circ Res. 2010 Apr 30;106(8):e6

Abstract

The immunoglobulin superfamily molecule RAGE (receptor for advanced glycation end product) transduces the effects of multiple ligands, including AGEs (advanced glycation end products), advanced oxidation protein products, S100/calgranulins, high-mobility group box-1, amyloid-beta peptide, and beta-sheet fibrils. In diabetes, hyperglycemia likely stimulates the initial burst of production of ligands that interact with RAGE and activate signaling mechanisms. Consequently, increased generation of proinflammatory and prothrombotic molecules and reactive oxygen species trigger further cycles of oxidative stress via RAGE, thus setting the stage for augmented damage to diabetic tissues in the face of further insults. Many of the ligand families of RAGE have been identified in atherosclerotic plaques and in the infarcted heart. Together with increased expression of RAGE in diabetic settings, we propose that release and accumulation of RAGE ligands contribute to exaggerated cellular damage. Stopping the vicious cycle of AGE-RAGE and RAGE axis signaling in the vulnerable heart and great vessels may be essential in controlling and preventing the consequences of diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Glucose – igniting mechanisms leading to accelerated atherosclerosis and myocardial infarction: inciting RAGE in diabetes
Central to diabetes is the development of hyperglycemia. We predict that very early in glucose intolerance or diabetes, elevated levels of glucose surpass a threshold; once beyond that threshold, AGEs accumulate (I) and stimulate RAGE. One consequence of RAGE signaling is the activation of NADPH oxidase (II) and production of ROS (III). Increased ROS may then contribute to increased production of AOPPs, more AGEs and AGE-modification of oxLDLs. Furthermore, increased ROS may deplete glutathione, thereby suppressing glyoxalase I activity – a mechanism favoring even further AGE accumulation (IV). AGEs, AOPPS, AGE-oxLDL ligands of RAGE sustain stimulation of RAGE and these processes, together with increased ROS, activate key transcription factors such as NF-kB and Egr-1 (V) which activate fundamental inflammatory mechanisms (VI). Consequences include increased migration and activation of RAGE-expressing neutrophils, monocytes/macrophages, T cells, and dendritic cells (VII). This results in release of the pro-inflammatory RAGE ligands S100/calgranulins and HMGB1. In this inflammatory environment, further AGEs may be formed as well. Via interaction with RAGE, these ligands magnify activation of NF-kB, Egr-1 and other factors (VIII), thereby amplifying cellular stress and tissue damage. In the aggregate, these processes may lead to accelerated atherosclerosis and increased myocardial damage in diabetes. Stopping the vicious cycle of RAGE ligand-RAGE interaction will be essential in curbing the maladaptive effects of glucose in diabetes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response – the evidence mounts. J Leukoc Biol. 2009;86:505–512. - PubMed
    1. Schmidt AM, Sahagan B, Nelson RB, Selmer J, Rothlein R, Bell JM. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer’s disease. Curr Opin Investig Drugs. 2009;10:672–680. - PubMed
    1. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53. - PMC - PubMed
    1. Dale AC, Vatten LJ, Nilsen TI, Midthjell K, Wiseth R. Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study. BMJ. 2008;337:a236. - PMC - PubMed
    1. Ahmed B, Bairey Merz CN, Johnson BD, Bittner V, Berga SL, Braunstein GD, Hodgson TK, Smith K, Shaw L, Kelsey SF, Sopko G WISE study group. Diabetes mellitus, hypothalamic hypoestrogenemia, and coronary artery disease in premenopausal women (from the National Heart, Lung, and Blood Institute sponsored WISE study) Am J Cardiol. 2008;102:150–154. - PMC - PubMed

Publication types

MeSH terms

Substances